Compare Abbott India with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs PANACEA BIOTECH - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA PANACEA BIOTECH ABBOTT INDIA/
PANACEA BIOTECH
 
P/E (TTM) x 44.5 12.3 362.7% View Chart
P/BV x 12.8 3.0 432.3% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 ABBOTT INDIA   PANACEA BIOTECH
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
PANACEA BIOTECH
Mar-18
ABBOTT INDIA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs6,110364 1,678.6%   
Low Rs3,996129 3,095.3%   
Sales per share (Unadj.) Rs1,552.296.8 1,603.8%  
Earnings per share (Unadj.) Rs188.8-12.4 -1,521.6%  
Cash flow per share (Unadj.) Rs196.4-2.9 -6,886.6%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.650.4 1,580.6%  
Shares outstanding (eoy) m21.2561.25 34.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.32.5 127.8%   
Avg P/E ratio x26.8-19.9 -134.7%  
P/CF ratio (eoy) x25.7-86.4 -29.8%  
Price / Book Value ratio x6.34.9 129.7%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,37615,101 711.0%   
No. of employees `0003.32.5 134.6%   
Total wages/salary Rs m3,9371,516 259.7%   
Avg. sales/employee Rs Th9,929.32,401.9 413.4%   
Avg. wages/employee Rs Th1,185.1614.2 192.9%   
Avg. net profit/employee Rs Th1,207.7-307.9 -392.2%   
INCOME DATA
Net Sales Rs m32,9855,928 556.4%  
Other income Rs m1,17082 1,421.5%   
Total revenues Rs m34,1556,010 568.3%   
Gross profit Rs m5,245845 620.5%  
Depreciation Rs m162585 27.7%   
Interest Rs m381,006 3.8%   
Profit before tax Rs m6,215-664 -936.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,20399 2,234.0%   
Profit after tax Rs m4,012-760 -527.9%  
Gross profit margin %15.914.3 111.5%  
Effective tax rate %35.4-14.9 -238.5%   
Net profit margin %12.2-12.8 -94.9%  
BALANCE SHEET DATA
Current assets Rs m22,6555,603 404.3%   
Current liabilities Rs m6,6816,910 96.7%   
Net working cap to sales %48.4-22.0 -219.7%  
Current ratio x3.40.8 418.2%  
Inventory Days Days65206 31.5%  
Debtors Days Days2984 34.8%  
Net fixed assets Rs m8359,941 8.4%   
Share capital Rs m21361 346.7%   
"Free" reserves Rs m16,7153,026 552.5%   
Net worth Rs m16,9283,087 548.4%   
Long term debt Rs m05,707 0.0%   
Total assets Rs m24,16216,076 150.3%  
Interest coverage x163.70.3 48,098.3%   
Debt to equity ratio x01.8 0.0%  
Sales to assets ratio x1.40.4 370.2%   
Return on assets %16.81.5 1,096.3%  
Return on equity %23.7-24.6 -96.3%  
Return on capital %36.93.9 943.2%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m3691,600 23.0%   
Fx outflow Rs m3,8071,131 336.4%   
Net fx Rs m-3,438469 -733.7%   
CASH FLOW
From Operations Rs m1,5271,180 129.4%  
From Investments Rs m-2,148553 -388.6%  
From Financial Activity Rs m-1,024-1,644 62.3%  
Net Cashflow Rs m-1,64690 -1,834.6%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.6 1,316.7%  
FIIs % 0.1 1.3 7.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 23.6 72.5%  
Shareholders   18,270 10,259 178.1%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  DR. DATSONS LABS  WOCKHARDT  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms Over 1,900 Points after Government Slashes Corporate Tax Rates(12:30 pm)

Share markets in India jumped sharply after FM Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 20, 2019 02:59 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS